Trials / Active Not Recruiting
Active Not RecruitingNCT03220646
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
A Phase 2 Study of Abemaciclib in Patients With Recurrent Primary Brain Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abemaciclib | abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle. |
| DRUG | abemaciclib | 200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C. |
Timeline
- Start date
- 2017-07-13
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2017-07-18
- Last updated
- 2025-07-09
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03220646. Inclusion in this directory is not an endorsement.